



CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-174 (all partially)

Monoclonal antibodies against TIP-2 and uses thereof as well
as hybridomas producing said antibodies

2. claims: 1-174 (all partially)

TIP-2 antigen/antigen fragments and uses thereof



European Patent
Office

**SUPPLEMENTARY
PARTIAL EUROPEAN SEARCH REPORT**

Application Number

which under Rule 45 of the European Patent Convention EP 01 97 3176
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 99/47929 A (THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK; TRAKHT, I) 23 September 1999 (1999-09-23) the whole document, especially page 60 line 34 - page 61 line 4 -----	1-174	C07K16/00 G01N33/53 C07K16/12 C07K16/28 C07K16/30 A61K39/395
X	EP 1 006 184 A (F. HOFFMANN-LA ROCHE AG) 7 June 2000 (2000-06-07) the whole document especially paragraphs 65, 66 -----	1-174	G01N33/574 G01N33/569 G01N33/68 C12N5/16 A61K39/00
P,X	WO 00/69898 A (ARBOR VITA CORPORATION; LU, PETER, S) 23 November 2000 (2000-11-23) the whole document, especially tables 2,3 and page 69 line 24-page 70 line 12 ----- -/--	1-174	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07K G01N
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
INCOMPLETE SEARCH			
The Search Division considers that the present application, or some or all of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for the following claims:			
Claims searched completely :			
Claims searched incompletely :			
Claims not searched :			
Reason for the limitation of the search: see sheet C			
Place of search		Date of completion of the search	Examiner
Munich		28 June 2005	Bayer, A
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

2
EPO FORM 1503 03.92 (P04C20)



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
L	KIRMAN IRENA ET AL: "Isolation of native human monoclonal autoantibodies to breast cancer." HYBRIDOMA AND HYBRIDOMICS, vol. 21, no. 6, December 2002 (2002-12), pages 405-414, XP002321206 ISSN: 1536-8599 * the whole document * -----	1-174	
L	KALANTAROV G F ET AL: "DEVELOPMENT OF A FUSION PARTNER CELL LINE FOR EFFICIENT PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES FROM PERIPHERAL BLOOD LYMPHOCYTES" HUMAN ANTIBODIES, AMSTERDAM, NL, vol. 11, 2002, pages 85-96, XP008032333 ISSN: 1093-2607 * the whole document * -----	1-174	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 97 3176

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-06-2005

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9947929	A	23-09-1999	US 6197582 B1	06-03-2001
			AU 3188999 A	11-10-1999
			CA 2323681 A1	23-09-1999
			EP 1064551 A1	03-01-2001
			JP 2002507398 T	12-03-2002
			WO 9947929 A1	23-09-1999
EP 1006184	A	07-06-2000	EP 1006184 A1	07-06-2000
			AU 728102 B2	04-01-2001
			AU 6305999 A	07-09-2000
			BE 1013527 A3	05-03-2002
			CA 2289914 A1	03-06-2000
			CH 694204 A5	15-09-2004
			DE 19958198 A1	08-06-2000
			DE 19964268 B4	29-01-2004
			FR 2788783 A1	28-07-2000
			GB 2347930 A , B	20-09-2000
			IE 991020 A1	28-06-2000
			IT MI992519 A1	04-06-2001
			JP 3294575 B2	24-06-2002
			JP 2000166555 A	20-06-2000
			JP 2001218599 A	14-08-2001
			NL 1013748 C2	28-12-2001
			NL 1013748 A1	06-06-2000
			SE 523013 C2	23-03-2004
			SE 9904389 A	04-06-2000
			US 2002146728 A1	10-10-2002
			US 6368826 B1	09-04-2002
			US 2004203062 A1	14-10-2004
			US 2005019832 A1	27-01-2005
			US 2004225114 A1	11-11-2004
			US 2002042389 A1	11-04-2002
WO 0069898	A	23-11-2000	AU 4352000 A	14-11-2000
			AU 5011200 A	05-12-2000
			AU 5011400 A	05-12-2000
			AU 5269800 A	05-12-2000
			EP 1169449 A2	09-01-2002
			EP 1178817 A2	13-02-2002
			JP 2004535751 T	02-12-2004
			JP 2002543825 T	24-12-2002
			WO 0061747 A2	19-10-2000
			WO 0069896 A2	23-11-2000
			WO 0069897 A2	23-11-2000
			WO 0069898 A2	23-11-2000
			US 2005019841 A1	27-01-2005

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 97 3176

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-06-2005

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0069898 A		US 2005037969 A1	17-02-2005
		AU 2107401 A	18-06-2001
		AU 2107601 A	18-06-2001
		AU 2269701 A	18-06-2001
		AU 2270201 A	18-06-2001
		EP 1238078 A2	11-09-2002
		WO 0142294 A2	14-06-2001
		WO 0142295 A2	14-06-2001
		WO 0142296 A2	14-06-2001
		WO 0142297 A2	14-06-2001
		US 2003103992 A1	05-06-2003
		US 2002102267 A1	01-08-2002
		US 2002169283 A1	14-11-2002
		US 2002086382 A1	04-07-2002



Although claims 71,74,79,80,86,87,157 and 158 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 60,126 and claims 19,30,40,50,112,137,140 as far as in vivo is concerned are directed to a diagnostic method practised on the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) not searched:

61-70,72,73,75-78,97,98,113-125,127-136,138,139,141,142

Reason for the limitation of the search:

Present claims 61-70,72,73,75-78,97,98,113-125,127-136,138,139,141 and 142 could not be searched due to a dependency on non-existing claims.

专利名称(译)	新型肿瘤相关标志物		
公开(公告)号	EP1326894A4	公开(公告)日	2005-08-31
申请号	EP2001973176	申请日	2001-09-18
[标]申请(专利权)人(译)	纽约市哥伦比亚大学理事会		
申请(专利权)人(译)	哥伦比亚大学纽约市受托人		
当前申请(专利权)人(译)	哥伦比亚大学纽约市受托人		
[标]发明人	TRAKHT ILYA CANFIELD ROBERT KALANTAROV GARY RUDCHENKO SERGEI		
发明人	TRAKHT, ILYA CANFIELD, ROBERT KALANTAROV, GARY RUDCHENKO, SERGEI		
IPC分类号	G01N33/543 A61K9/127 A61K39/395 A61K47/48 A61P5/00 A61P19/02 A61P29/00 A61P31/00 A61P31/04 A61P31/10 A61P31/12 A61P31/14 A61P31/16 A61P31/18 A61P31/20 A61P31/22 A61P35/00 A61P37/02 A61P37/04 A61P37/06 A61P39/02 A61P43/00 C07K7/06 C07K16/12 C07K16/28 C07K16/30 C12N5/10 C12N5/16 C12N5/26 C12P21/08 C12Q1/68 G01N33/569 G01N33/574 G01N33/577 G01N33/68 C07K16/00 G01N33/53 A61K39/00		
CPC分类号	A61P19/02 C07K16/28 C07K16/3015 C07K2317/21 C07K2317/77 C12N5/163 C12N5/166 C12N2510/02 C12N2510/04 G01N33/57407 G01N33/57492		
优先权	09/664958 2000-09-18 US		
其他公开文献	EP1326894B1 EP1326894A2		
外部链接	Espacenet		

摘要(译)

本发明提供了产生单克隆抗体的杂交瘤，命名为27.F7和27.B1。本发明提供了一种检测样品中带有TIP-2抗原的癌细胞的方法。本发明提供了一种检测癌细胞表面上的TIP-2抗原的方法。本发明提供了一种用于诊断受试者的癌症的方法。本发明提供了将外源物质递送至人受试者的携带TIP-2抗原的癌细胞的方法。本发明提供了一种治疗人类受试者的癌症的方法。本发明提供了具有氨基酸序列Lys Leu Leu Gly Gly Gln Ile Gly Leu (SEQ. ID No.) 和Ser Leu Leu Gly Cys Arg His Tyr Glu Val (SEQ. ID No.) 的分离的肽。本发明提供了一种用于免疫组织化学筛选组织切片中是否存在携带TIP-2抗原的癌细胞的方法。本发明提供了用于检测带有TIP-2抗原的癌细胞的存在试剂盒。本发明提供了一种检测TIP-2抗原的存在的方法。本发明提供了用于免疫组织化学筛选组织切片的方法。本发明提供了一种监测癌症进展的方法，其中所述癌细胞是带有TIP-2抗原的细胞。本发明提供了一种诊断与TIP-2表达有关的癌症的方法。

Place of search	Date of completion of the search	Examiner
Munich	28 June 2005	Bayer, A
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		& : member of the same patent family, corresponding document